NEW YORK --(BUSINESS WIRE)--Jan. 31, 2023-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in the SVB Securities Global Biopharma Conference and will give a
NEW YORK --(BUSINESS WIRE)--Jan. 20, 2023-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on January 16, 2023 , the company granted (i) non-statutory stock options to purchase an
New Target Added to Ongoing Collaboration with Bristol Myers Squibb Unveils LRRK2 Inhibitor Program Targeting Neurodegenerative Diseases New Collaboration and Software Agreement with Otsuka Pharmaceutical Co., Ltd. NEW YORK --(BUSINESS WIRE)--Jan. 9, 2023-- Schrödinger , Inc.